AAAAAA

   
Results: 1-12 |
Results: 12
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1
Authors: Spenlehauer, C Gordon, CA Trkola, A Moore, JP
Citation: C. Spenlehauer et al., A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1, VIROLOGY, 280(2), 2001, pp. 292-300
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
Authors: Strizki, JM Xu, S Wagner, NE Wojcik, L Liu, J Hou, Y Endres, M Palani, A Shapiro, S Clader, JW Greenlee, WJ Tagat, JR McCombie, S Cox, K Fawzi, AB Chou, CC Pugliese-Sivo, C Davies, L Moreno, ME Ho, DD Trkola, A Stoddart, CA Moore, JP Reyes, GR Baroudy, BM
Citation: Jm. Strizki et al., SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo, P NAS US, 98(22), 2001, pp. 12718-12723
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
Authors: Trkola, A Ketas, TJ Nagashima, KA Zhao, L Cilliers, T Morris, L Moore, JP Maddon, PJ Olson, WC
Citation: A. Trkola et al., Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140, J VIROLOGY, 75(2), 2001, pp. 579-588
The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity
Authors: Proudfoot, AEI Fritchley, S Borlat, F Shaw, JP Vilbois, F Zwahlen, C Trkola, A Marchant, D Clapham, PR Wells, TNC
Citation: Aei. Proudfoot et al., The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity, J BIOL CHEM, 276(14), 2001, pp. 10620-10626
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
Authors: Dragic, T Trkola, A Thompson, DAD Cormier, EG Kajumo, FA Maxwell, E Lin, SW Ying, WW Smith, SO Sakmar, TP Moore, JP
Citation: T. Dragic et al., A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5, P NAS US, 97(10), 2000, pp. 5639-5644
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection
Authors: Binley, JM Trkola, A Ketas, T Schiller, D Clas, B Little, S Richman, D Hurley, A Markowitz, M Moore, JP
Citation: Jm. Binley et al., The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection, J INFEC DIS, 182(3), 2000, pp. 945-949
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
Authors: Jacobson, JM Lowy, I Fletcher, CV O'Neill, TJ Tran, DNH Ketas, TJ Trkola, A Klotman, ME Maddon, PJ Olson, WC Israel, RJ
Citation: Jm. Jacobson et al., Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults, J INFEC DIS, 182(1), 2000, pp. 326-329
Antagonism of chemokine receptors in preventing infection by HIV
Authors: Proudfoot, AEI Wells, TNC Trkola, A
Citation: Aei. Proudfoot et al., Antagonism of chemokine receptors in preventing infection by HIV, ANTIVIRALS AGAINST AIDS, 2000, pp. 249-267
The CC-chemokine RANTES increases the attachment of human immunodeficiencyvirus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity
Authors: Trkola, A Gordon, C Matthews, J Maxwell, E Ketas, T Czaplewski, L Proudfoot, AEI Moore, JP
Citation: A. Trkola et al., The CC-chemokine RANTES increases the attachment of human immunodeficiencyvirus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity, J VIROLOGY, 73(8), 1999, pp. 6370-6379
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor
Authors: Trkola, A Matthews, J Gordon, C Ketas, T Moore, JP
Citation: A. Trkola et al., A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor, J VIROLOGY, 73(11), 1999, pp. 8966-8974
Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion
Authors: Gordon, CJ Muesing, MA Proudfoot, AEI Power, CA Moore, JP Trkola, A
Citation: Cj. Gordon et al., Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion, J VIROLOGY, 73(1), 1999, pp. 684-694
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
Authors: Ortiz, GM Nixon, DF Trkola, A Binley, J Jin, X Bonhoeffer, S Kuebler, PJ Donahoe, SM Demoitie, MA Kakimoto, WM Ketas, T Clas, B Heymann, JJ Zhang, LQ Cao, YZ Hurley, A Moore, JP Ho, DD Markowitz, M
Citation: Gm. Ortiz et al., HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy, J CLIN INV, 104(6), 1999, pp. R13-R18
Risultati: 1-12 |